CompletedNCT02942017
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
Medication studyAges 18–45United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
- Listed locations
- Chandler and 31 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 108
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT02942017
- Official title
Show the full official title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects With Severe Postpartum Depression and Adult Female Subjects With Moderate Postpartum Depression
Get this study by email
Recruitment & locations
CompletedChandler · Rogers · Lemon Grove
28 more locations
- Orange
- Ventura
- Gainesville
- Miami
- Miramar
- Orlando
- Pensacola
- Pinellas Park
- Atlanta
- Hoffman Estates
- Wichita
- Edgewood
- Owensboro
- Boston
- Flowood
- Marlton
- Glen Oaks
- Chapel Hill
- Charlotte
- Raleigh
- Columbus
- Dayton
- Philadelphia
- Baytown
- Houston
- Richardson
- San Antonio
- Orem
Questions about this study
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo and SAGE-547 90 μg/kg/h.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
